Prescription Drug Abuse: A Call to Action
The Prescription Drug Abuse Prevention Plan creates four focus areas for addressing this problem: 1) improving education for the public, patients and healthcare providers, 2) supporting the expansion of state-based prescription drug monitoring programs (PDMPs), 3) recommending more convenient and environmentally responsible disposal methods to remove unneeded or expired medications from circulation, and 4) reducing the prevalence of pill mills and doctor shopping through enforcement efforts. The presentation will address each of these four pillars.
The National Drug Control Strategy recognizes that prevention through early detection and treatment of prescription drug misuse or abuse by a health care professional is a cost-effective approach to solving this problem. The Strategy also recognizes the importance of making antidotes like naloxone widely available and educating the public about its use. The Administration has prioritized reducing overdose deaths, setting a specific goal to reduce such deaths by 15% by 2015. The presentation will discuss methods for implementing early intervention and treatment programs and increasing utilization of naloxone for first responders.
Planning of health education strategies, interventions, and programs
Public health or related public policy
Explain the rationale and action steps to prevent prescription drug misuse or abuse through early detection and treatment as a cost-effective approach.
Qualified on the content I am responsible for because: Deputy Director Botticelli has served in a variety of leadership roles for the National Association of State Alcohol and Drug Abuse Directors. He was also a member of the Advisory Committee for the Substance Abuse and Mental Health Services Administrationâs Center for Substance Abuse Prevention and the National Action Alliance for Suicide Prevention. He has also co-authored many peer-reviewed articles that have significantly contributed to the substance abuse field.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.